Seeking Alpha

Valeant Pharmaceuticals (VRX -1.4%) receives U.S. antitrust approval for its $24/share...

Valeant Pharmaceuticals (VRX -1.4%) receives U.S. antitrust approval for its $24/share acquisition of Obagi Medical (OMPI). The deal now needs the authorization of the Antimonopoly Committee of Ukraine. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)